Catalyst Pharmaceuticals Acquired by Angelini | Healthcare M&A Deal

Angelini has completed the acquisition of Catalyst Pharmaceuticals, a physician practice business in the healthcare sector in the U.S., for $4.1 billion. Angelini acquires Catalyst Pharmaceuticals to expand its CNS and rare neuro disorder portfolio through three marketed central nervous system medicines, including Firdapse for Lambert-Eaton myasthenic syndrome and Fycompa for partial and tonic-clonic seizures. Catalyst Pharmaceuticals also markets Agamree, a steroid treatment for Duchenne muscular dystrophy, generating $589 million in revenue and guiding 2026 total revenue of $615 million to $645 million. The strategic acquisition is structured as a platform acquisition and is valued at $31.50 per Catalyst share, representing a 21% premium, with integration planned across Angelini’s brain health capabilities and Catalyst’s commercial infrastructure.